Titan Pharmaceuticals, Inc.

NASDAQ: TTNP    
Share price (4/26/24): $7.09    
Market cap (4/26/24): $6.482 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.4
from 8-K 4 pages Settlement Agreement and General and Mutual Release
12/34/56
EX-10.3
from 8-K 4 pages Settlement Agreement and General and Mutual Release
12/34/56
EX-10.2
from 8-K 3 pages Agreement
12/34/56
EX-10.1
from 8-K 4 pages Form of Settlement Agreement and General and Mutual Release
12/34/56
EX-10.4
from 10-Q 20 pages Convertible Promissory Note
12/34/56
EX-10.2
from 8-K/A 12 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K/A 38 pages Securities Purchase Agreement
12/34/56
EX-10.2
from 8-K 12 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 38 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 26 pages *** Certain Identified Information Has Been Excluded (Denoted by the Symbol “[****]”) From the Exhibit Because Such Information Is Both (I) Not Material and (II) Would Likely Cause Competitive Harm to the Company if Publicly Disclosed. Amendment and Extension Agreement
12/34/56
EX-10.4
from 10-Q 20 pages Convertible Promissory Note
12/34/56
EX-10.2
from 8-K 3 pages Unsecured Promissory Note
12/34/56
EX-10.1
from 8-K 54 pages Asset Purchase Agreement by and Between Titan Pharmaceuticals, Inc. and Fedson, Inc. July 26, 2023
12/34/56
EX-10.18
from 10-Q 2 pages 2023 Amendment to Employment Agreement
12/34/56
EX-10.1
from 8-K 11 pages Employment Agreement
12/34/56
EX-10.1
from 8-K 37 pages License Agreement Between Titan Pharmaceuticals, Inc. and Ocular Therapeutix, Inc. Dated as of December 6, 2022
12/34/56
EX-10.2
from 10-Q 18 pages Titan Pharmaceuticals, Inc. Fifth Amended and Restated 2015 Omnibus Equity Incentive Plan as Amended [●], 2022
12/34/56
EX-10.1
from 10-Q 7 pages Stand-Alone Stock Option Agreement
12/34/56
EX-10.1
from 8-K 7 pages Stand-Alone Stock Option Agreement
12/34/56
EX-10.2
from 8-K 2 pages Amendment No. 2 to Employment Agreement
12/34/56